电邮这篇文章 Modern external therapy moderately severe forms of rosacea
- 作者: Olisova O.Y.1, Kochergin N.G1, Smirnova E.A.2
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University
- “LMS Clinic”
- 期: 卷 19, 编号 6 (2016)
- 页面: 328-334
- 栏目: Articles
- URL: https://bakhtiniada.ru/1560-9588/article/view/37150
- DOI: https://doi.org/10.18821/1560-9588-2016-19-6-328-334
- ID: 37150
如何引用文章
全文:
详细
The scientific review of modern approaches to the etiology and pathophysiology of rosacea is presented. The features of the disease, importance and possibility of reducing or eliminating the symptoms of the disease for the patient and the doctor in the early stages are shown. The various sources highlighted the frequent and specific, common and rare species of clinical picture of the disease are analyzed. Specific and differentiating symptoms are presented. The “steroid rosacea”, the reasons for occurrence, the difficulty faced by the doctor during the treatment and the possibility of torpid course are described. There was a contradiction of researcher’s views about approaches to the etiology, pathogenesis of the disease and the experimental data. The classification of the rosacea forms, drugs and therapy of moderately severe forms of rosacea are presented. The new topical drugs for the treatment of this disease are described. Results on the methods of topical treatment of moderate forms of rosacea, the results of several double-blind, placebo-controlled studies in the US and Canada, the effectiveness of treatment of rosacea with modern drugs (ivermectin, brimonidine) compared to traditional (in particular, with azelaic acid) are presented. In conclusion high effectiveness, good tolerability and safety of drugs ivermectin (Soolantra) and brimonidine (Mirvaso® Derm) (Galderma, Switzerland) are shown. It is suggested to include the above-mentioned drugs to the Russian standards of treatment of moderately severe forms of rosacea.
作者简介
O. Olisova
I.M. Sechenov First Moscow State Medical UniversityDepartment of Skin and Venereal Diseases Moscow, 119991, Russian Federation
N. Kochergin
I.M. Sechenov First Moscow State Medical UniversityDepartment of Skin and Venereal Diseases Moscow, 119991, Russian Federation
Elena Smirnova
“LMS Clinic”
Email: doctor.e.smirnova@gmail.com
dermatovenerologist, LLC “LMS Clinic” Moscow, 119146, Russian Federation
参考
- Самцов А.В. Акне и акнеформные дерматозы. М.: ФАРМТЕК 2014.
- Олисова О.Ю., Додина М.И. Современные представления о патогенезе розецеа. Экспериментальная и клиническая дерматокосметология. 2010; 6: 18-22.
- Phillips T.J. An update on the safety and efficacy of topical retinoids. Cutis. 2005; 75(2): 14-22.
- Aziz N., Khachemoune A. A man with changes on nose. J. Am. Acad. Dermatol. 2007; 57(3): 551-54. http://www.jaad.org/article/S0190-9622(07)00875-4/abstract.
- Dirschka T., Micali G., Papadopoulos L., Tan J., Layton A., Moore S., et al. Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey. Dermatol. Ther. (Heidelb). 2015; 5(Issue 2): 117-27.
- Музыченко А.П. Розацеа: Учебно-методическое пособие. Минск: БГМУ; 2014.
- Кубанова А.А., ред. Дерматовенерология. М.:ДЭКС-Пресс; 2010.
- Ильина И.В., Санакоева Э.Г., Масюкова С.А. Современная терапия акне и акнеформных дерматозов. Экспериментальная и клиническая дерматокосметология. 2011; 1: 18-20.
- Пинсон И.Я., Верхогляд И.В., Семочкин А.В. Современные представления об этиологии и патогенезе розацеа. Экспериментальная и клиническая дерматокосметология. 2012; 5: 21-4.
- Вольф К., Голдсмит Л.А., Кац С.И., Джилкрест Б.А., Паллер Э.С., Леффель Д.Дж. Дерматология Фицпатрика в клинической практике. Пер. с англ. М.: Изд. Панфилова; БИНОМ; 2012. т.1: 769-74.
- Ахтямов С.Н. Практическая дерматокосметология. Акне, рубцы постакне и акнеформные дерматозы: Руководство для врачей. М.: Медицина; 2010.
- Dahl M.V., Ross A.J., Shlievert P.M. Temperature regulates bacterial protein production: possible role in rosacea. J. Am. Acad. Dermatol. 2004; 50(2): 266-72.
- Кубанова А.А., Махакова Ю.Б. Розацеа: диагностика и лечение. Вестник дерматологии и венерологии. 2015; 3: 36-45.
- Катханова О.А., Стенин А.В. Комплексная терапия акнеформных дерматозов. Экспериментальная и клиническая дерматокосметология. 2014; 2: 1-6.
- Молочков А.В., Овсянникова Г.В. Метранидазол в наружном лечении розацеа. Клиническая дерматология и венерология. 2010; 2: 82-4.
- Пашинян А.Г. Лечение розацеа. Клиническая дерматология и венерология. 2009; 1: 64-6.
- Пашинян А.Г. Фармакотерапия розацеа. Лечащий врач. 2007; 9: 5-8.
- Санакоева Э.Г., Масюкова С.А., Ильина И.В., Введенская Э.В., Плиева Д.В., Алиева П.М., Мамашева Г.Д.Современная терапия акне и акне и акнеформных дерматозов. Российский журнал кожных и венерических болезней. 2013; 16(6): 37-42.
- Wilkin J.K. Rosacea. Pathophisiologia and treatment. Arch. Dermatol. 1994; 130(3): 359-62.
- Кочергин Н.Г., Румянцева Е.Е., Кондрашов Г.В, Траксель Е.В. Пимекролимус при иммунодерматозах. Русский медицинский журнал. 2003; 11(17, вып. 189): 953-56.
- Пашинян А.Г. Терапия больных различными клиническими формами розацеа. Вестник дерматологии и венерологии. 2010; 6: 83-5.
- Stein L., Kircik L., Fowler J., Tan J., Draelos Z., Fleischer A., et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J. Drugs Dermatol. 2014; 13(3): 316-23.
- Stein L., Kircik L., Fowler J., Jackson J.M., Tan J., Draelos Z., et al.; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigatorblinded trials. J. Drug Dermatol. 2014; 13(11): 1380-6.
- Fowler J., Jackson M., Moore A., Jarratt M., Jones T., Meadows K., et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J. Drugs Dermatol. 2013; 12(6): 650-6.
- Moore A., Kempers S., Murakawa G., Weiss J., Tauscher A., Swinyer L., et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year openlabel study. J. Drugs Dermatol. 2014; 13(1): 56-64.
补充文件
